Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Current Assets (2018 - 2025)

Historic Current Assets for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $738.8 million.

  • Bicycle Therapeutics' Current Assets fell 2353.31% to $738.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $738.8 million, marking a year-over-year decrease of 2353.31%. This contributed to the annual value of $928.6 million for FY2024, which is 6527.1% up from last year.
  • Latest data reveals that Bicycle Therapeutics reported Current Assets of $738.8 million as of Q3 2025, which was down 2353.31% from $804.3 million recorded in Q2 2025.
  • Bicycle Therapeutics' Current Assets' 5-year high stood at $1.0 billion during Q2 2024, with a 5-year trough of $215.4 million in Q1 2021.
  • Its 5-year average for Current Assets is $555.1 million, with a median of $458.6 million in 2021.
  • Per our database at Business Quant, Bicycle Therapeutics' Current Assets surged by 19446.84% in 2021 and then tumbled by 2353.31% in 2025.
  • Quarter analysis of 5 years shows Bicycle Therapeutics' Current Assets stood at $458.6 million in 2021, then fell by 19.45% to $369.4 million in 2022, then skyrocketed by 52.11% to $561.9 million in 2023, then skyrocketed by 65.27% to $928.6 million in 2024, then decreased by 20.44% to $738.8 million in 2025.
  • Its last three reported values are $738.8 million in Q3 2025, $804.3 million for Q2 2025, and $856.1 million during Q1 2025.